Jane Street Group LLC bought a new stake in Opthea Limited (NASDAQ:OPT – Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 26,632 shares of the company’s stock, valued at approximately $114,000.
Analyst Upgrades and Downgrades
Separately, Canaccord Genuity Group upgraded shares of Opthea to a “strong-buy” rating in a report on Tuesday, December 17th.
Check Out Our Latest Analysis on OPT
Opthea Price Performance
About Opthea
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Featured Stories
- Five stocks we like better than Opthea
- Why is the Ex-Dividend Date Significant to Investors?
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- 3 Best Fintech Stocks for a Portfolio Boost
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- Investing In Automotive Stocks
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Want to see what other hedge funds are holding OPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Opthea Limited (NASDAQ:OPT – Free Report).
Receive News & Ratings for Opthea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opthea and related companies with MarketBeat.com's FREE daily email newsletter.